Research programme: proteoglycan-like compounds (vascular injuries) - Symic Bio
Latest Information Update: 28 Oct 2019
Price :
$50 *
At a glance
- Originator SYMIC Biomedical
- Developer Symic Bio
- Class Proteoglycans
- Mechanism of Action Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arteriovenous fistula; Vascular disorders
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Arteriovenous-fistula in USA (Parenteral)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Vascular-disorders in USA (Parenteral)
- 26 Aug 2015 Preclinical trials in Arteriovenous fistula in USA (Parenteral)